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Introduction {#brb3451-sec-0005}
============

Charcot--Marie--Tooth (CMT) neuropathy (also called hereditary motor and sensory neuropathy or HMSN) is a rare disorder with a prevalence of one in 2500 (Skre [1974](#brb3451-bib-0034){ref-type="ref"}). CMT is clinically characterized by muscle wasting and weakness in the distal limbs resulting in steppage gait as well as distal sensory loss. Foot deformities such as pes cavus and hammer toes are frequently present (Rossor et al. [2013](#brb3451-bib-0030){ref-type="ref"}; Timmerman et al. [2014](#brb3451-bib-0040){ref-type="ref"}). Usually, the disease course is slowly progressive and in some cases, the use of a walker or wheelchair is necessary later in life (Timmerman et al. [2014](#brb3451-bib-0040){ref-type="ref"}). Besides the classical clinical appearance of CMT patients, additional symptoms have been described in association with mutations in certain genes, such as pupil abnormalities with mutations in the myelin protein zero (*MPZ*) gene (De Jonghe et al. [1999](#brb3451-bib-0011){ref-type="ref"}; Hattori et al. [2003](#brb3451-bib-0019){ref-type="ref"}; Stojkovic et al. [2003](#brb3451-bib-0035){ref-type="ref"}), hearing impairment in association with pathogenic variants in the gap junction protein beta 1 (*GJB1*) gene (Hattori et al. [2003](#brb3451-bib-0019){ref-type="ref"}), or focal segmental glomerular sclerosis (FSGS) with mutations in the inverted formin 2 (*INF2*) gene (Boyer et al. [2011](#brb3451-bib-0006){ref-type="ref"}; Mademan et al. [2013](#brb3451-bib-0023){ref-type="ref"}).

CMT has been subdivided into three forms by nerve conduction velocity (NCV) studies: a demyelinating form with motor NCV in the upper limbs below 38 m/sec (CMT1), an axonal form with NCV above 38 m/sec (CMT2) (Harding and Thomas [1980](#brb3451-bib-0017){ref-type="ref"}), and an intermediate form with NCV between 25 and 45 m/sec (Davis et al. [1978](#brb3451-bib-0010){ref-type="ref"}). The neuropathological hallmark of CMT1 is segmental de‐ and remyelination and onion bulb formations. In CMT2 patients, nerve biopsies typically show axonal loss and regenerative sprouting (Schröder [2001](#brb3451-bib-0032){ref-type="ref"}). Both histopathological abnormalities are present in intermediate CMT. At the molecular genetic level, CMT is very heterogeneous with mutations in over 80 causative genes known so far and all possible modes of inheritance (Azzedine et al. [2012](#brb3451-bib-0002){ref-type="ref"}; Timmerman et al. [2014](#brb3451-bib-0040){ref-type="ref"}). The most frequently mutated gene is peripheral myelin protein 22 (*PMP22*), leading to CMT1A (duplication or point mutation) or hereditary neuropathy with liability to pressure palsies (HNPP, deletion or point mutation) (van Paassen et al. [2014](#brb3451-bib-0028){ref-type="ref"}). Novel parallel gene sequencing techniques \[next‐generation sequencing (NGS), whole‐exome sequencing (WES)\] are nowadays available (Rossor et al. [2013](#brb3451-bib-0030){ref-type="ref"}); however, the costs for WES in a diagnostic setting are still high and not (yet) covered by health insurances in many countries. Furthermore, the novel genetic techniques usually lead to a large number of variants of which the causative relation with the disease is often unclear.

Here, we studied the occurrence of additional features in a large cohort of genetically defined CMT patients and performed a systematic revision of the literature. We explored whether the presence of diverse associated clinical features, such as hypertrophic nerve roots or pupil abnormalities, might contribute to identify the causative gene in CMT patients. We also examined whether the occurrence of additional features correlated with the CMTNS2 neuropathy severity score.

Patients and Methods {#brb3451-sec-0006}
====================

Patient selection {#brb3451-sec-0007}
-----------------

We included 49 patients with genetically confirmed CMT or HNPP that were followed in our neuromuscular outpatient clinic (Department of Neurology, University Hospital RWTH Aachen, Germany) from January 2010 to December 2014 (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). In addition, we searched the database of the Department of Nephrology (University Hospital RWTH Aachen, Germany) for patients born after 1970 presenting focal segmental glomerular sclerosis (FSGS) diagnosed on kidney biopsy. We identified 20 FSGS patients and screened them for an additional polyneuropathy, using a questionnaire on neuropathy symptoms and a clinical neurological examination. The study was approved by the ethical committee of the RWTH University Aachen, Germany.

###### 

Genetic data, CMTNS2 scores and CMT subtype of the patients included in the study (*N* = 49)

  Patient (Family)   Gender/AAE   CMTNS2/at AAE   Gene         CMT subtype    Mutation            Protein change     SIFT                PolyPhen‐2              Provean Sift      References
  ------------------ ------------ --------------- ------------ -------------- ------------------- ------------------ ------------------- ----------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1 (S)**          **M/27**     ***2*** **5**   ***MPZ***    **CMT1B**      **c.678delC**       **p.S226fs**       **na**              **na**                  **na**            **Novel**
  2 (F1)             M/51         16              *MPZ*        CMT1B          c.487G\>A           p.G163R            Not tolerated       Probably damaging       Deleterious       Street et al. ([2002](#brb3451-bib-0036){ref-type="ref"}); Eggers et al. ([2004](#brb3451-bib-0012){ref-type="ref"})
  3 (F1)             M/78         ND              *MPZ*        CMT1B          c.487G\>A           p.G163R            Not tolerated       Probably damaging       Deleterious       Street et al. ([2002](#brb3451-bib-0036){ref-type="ref"}); Eggers et al. ([2004](#brb3451-bib-0012){ref-type="ref"})
  4 (F1)             F/46         10              *MPZ*        CMT1B          c.487G\>A           p.G163R            Not tolerated       Probably damaging       Deleterious       Street et al. ([2002](#brb3451-bib-0036){ref-type="ref"}); Eggers et al. ([2004](#brb3451-bib-0012){ref-type="ref"})
  **5**              **F/30**     **2**           ***MPZ***    **CMT2‐I/J**   **c.368G\>C**       **p.G123A**        **Not tolerated**   **Probably damaging**   **Deleterious**   **Novel**
  6                  M/68         14              *MPZ*        CMT1B          c.293G\>A           p.R98H             Not tolerated       Probably damaging       Deleterious       Gabreels‐Festen et al. ([1996](#brb3451-bib-0014){ref-type="ref"}); Watanabe et al. ([2002](#brb3451-bib-0042){ref-type="ref"})
  **7 (F2)(S)**      **F/44**     **29**          ***MPZ***    **CMT1B**      **c.103_104insA**   **p.L35fsX66**     **na**              **na**                  **na**            **Novel**
  **8 (F2)(S)**      **M/70**     **4**           ***MPZ***    **CMT1B**      **c.103_104insA**   **p.L35fsX66**     **na**              **na**                  **na**            **Novel**
  **9 (F2)(S)**      **M/41**     **0**           ***MPZ***    **CMT1B**      **c.103_104insA**   **p.L35fsX66**     **na**              **na**                  **na**            **Novel**
  10                 F/48         27              *MPZ*        CMT2‐I/J       c.293G\>A           p.R98H             Not tolerated       Probably damaging       Deleterious       Gabreels‐Festen et al. ([1996](#brb3451-bib-0014){ref-type="ref"}); Watanabe et al. ([2002](#brb3451-bib-0042){ref-type="ref"})
  11                 M/64         22              *MPZ*        CMT1B          c.670G\>T           p.D224Y            Not tolerated       Probably damaging       Deleterious       Fabrizi et al. ([2006](#brb3451-bib-0013){ref-type="ref"})
  12 (F3)            M/33         6               *LITAF*      CMT1C          c.430G\>A           p.V144M            Not tolerated       Probably damaging       Damaging          Gerding et al. ([2009](#brb3451-bib-0015){ref-type="ref"})
  13 (F3)            F/54         22              *LITAF*      CMT1C          c.430G\>A           p.V144M            Not tolerated       Probably damaging       Damaging          Gerding et al. ([2009](#brb3451-bib-0015){ref-type="ref"})
  14                 M/51         21              *GJB1*       CMTX1          c.547C\>A           p.R183S            Not tolerated       Probably damaging       Deleterious       Bort et al. ([1997](#brb3451-bib-0005){ref-type="ref"})
  15                 F/38         18              *GJB1*       CMTX1          c.8G\>A             p.W3X              na                  na                      na                Ananth U ([\[Link\]](#brb3451-bib-0120){ref-type="ref"}), private data
  **16 (F4)**        **F/45**     **15**          ***GJB1***   **CMTX1**      **c.303dup**        **p.E102Rfs\*8**   **na**              **na**                  **na**            **Novel**
  **17 (F4)**        **M/39**     **18**          ***GJB1***   **CMTX1**      **c.303dup**        **p.E102Rfs\*8**   **na**              **na**                  **na**            **Novel**
  18                 M/48         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  19                 M/37         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  20                 F/26         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  21                 F27          na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  22                 F/33         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  23                 M/51         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  24 (F5)            F/65         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  25 (F5)            F/40         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  26                 F/56         na              *PMP22*      HNPP           Deletion            Deletion           na                  na                      na                Chance et al. ([1993](#brb3451-bib-0170){ref-type="ref"})
  27 (F6)            F/49         21              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  28 (F6)            F/70         18              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski, et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  29                 M/23         11              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  30                 F/26         24              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  31                 M/30         25              *PMP22*      CMT1A          c.256C\>T           p.Q86X             na                  na                      na                Numakura et al. ([2002](#brb3451-bib-0027){ref-type="ref"})
  32                 M/62         7               *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  33                 M/42         14              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  34                 M/59         26              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  35                 F/49         31              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  36                 F/56         21              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  37 (F7)            F/66         24              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  38 (F7)            M/45         19              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  39                 F/51         20              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  40                 M/63         27              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  41                 F/46         16              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  42                 F/34         ND              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  43 (F8)            F/8          5               *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  44 (F8)            F/45         24              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  45                 F/51         26              *PMP22*      CMT1A          Duplication         Duplication        na                  na                      na                Lupski et al. ([1991](#brb3451-bib-0300){ref-type="ref"}); Raeymaekers et al. ([1991](#brb3451-bib-0400){ref-type="ref"})
  46                 M/45         13              *NEFL*       CMT1F          c.995A\>C           p.Q332P            Not tolerated       Probably damaging       Deleterious       Mersiyanova et al. ([2000](#brb3451-bib-0025){ref-type="ref"})
  47                 F/12         ND              *INF2*       CMTDIE         c.230T\>G           p.L77R             Not tolerated       Probably damaging       Deleterious       Mademan et al. ([2013](#brb3451-bib-0023){ref-type="ref"})
  48                 F/32         ND              *MFN2*       CMT2A2         c.839G\>A           p.R280H            Not tolerated       Probably damaging       Deleterious       Zuchner et al. ([2004](#brb3451-bib-0044){ref-type="ref"}); Chung et al. ([2006](#brb3451-bib-0009){ref-type="ref"}); Verhoeven et al. ([2006](#brb3451-bib-0041){ref-type="ref"})
  49                 M/42         21              *MFN2*       CMT2A2         c.281G\>A           p.R94Q             Not tolerated       Probably damaging       Deleterious       Zuchner et al. ([2004](#brb3451-bib-0044){ref-type="ref"}); Chung et al. ([2006](#brb3451-bib-0009){ref-type="ref"}); Verhoeven et al. ([2006](#brb3451-bib-0041){ref-type="ref"})

AAE, age at examination; CMTNS2, Charcot--Marie--Tooth neuropathy score version 2 (score ranging from 0 to 36); mild: 0--10; moderate: 11--20; severe neuropathy: \>20; CMT, Charcot--Marie--Tooth neuropathy; HNPP, hereditary neuropathy with liability to pressure palsies. In bold, the novel mutations are indicated. SIFT, sorting intolerant from tolerant algorithm; PolyPhen‐2, polymorphism phenotyping version 2; Provean Sift, protein variation effect analyzer; S, segregation analysis was performed in the patient\'s family. Families are marked with F followed by the family number; na, not applicable; ND, not done; Gene abbreviations: *MPZ* = myelin protein zero; *LITAF* = lipopolysaccharide‐induced tumor necrosis factor‐alpha factor; *GJB1 *=* *gap junction protein, beta‐1; *PMP22 *=* *peripheral myelin protein 22; *NEFL* = neurofilament protein, light polypeptide; *INF2 *=* *inverted formin 2; *MFN2 *=* *mitofusin 2.
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Clinical and paraclinical examinations {#brb3451-sec-0008}
--------------------------------------

In all patients, we performed a detailed history taking, and general clinical and neurological examination with particular attention for additional features (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}). The feature cold‐induced hand cramps was asked for anamnestically and the presence of scoliosis was derived from the patients\' medical reports in a retrospective manner. We applied the CMT neuropathy score version 2 (CMTNS2) in 37 patients, in order to evaluate the severity of neuropathy: mild (range 0--10), moderate (range 11--20), or severe (\>20, maximum 36) (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}) (Murphy et al. [2011](#brb3451-bib-0026){ref-type="ref"}). We systematically performed motor and sensory nerve conduction velocities (NCV) at the upper limbs in all patients and additionally at the lower limbs in some. Prior to this study, a lumbar puncture was performed in two CMT patients (patients 2 and 6), a magnetic resonance imaging (MRI) of the thoraco‐lumbo‐sacral spine (Philips Intera, 1.5 Tesla, Andover, MA) in patients 2, 4, 6, 7, and 13, a MRI of the cervical spine in patient 12 and a MRI of the brain in patients 1, 2, 5, 6, 12, and 22 for diagnostic purposes. Sural nerve biopsies were obtained previous to the study for diagnostic reasons in patients 1, 2, 6, 23, 24, and 47, after written informed consent. The biopsies were processed following standard procedures (Weis et al. [2012](#brb3451-bib-0043){ref-type="ref"}). Semithin sections were stained with toluidine blue and both light and electron microscopic studies were performed.

###### 

Additional symptoms and features identified in our CMT cohort (*N* = 49)

  Mutated gene                *MPZ*                                                                                              *PMP22* (CMT1A)                                                       *PMP22* (HNPP)                     *GJB1*       *NEFL*   *INF2*                                           *LITAF*                                            *MFN2*
  --------------------------- -------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------- ------------ -------- ------------------------------------------------ -------------------------------------------------- -----------------------
  Number of patients          11                                                                                                 19                                                                    9                                  4            1        1                                                2                                                  2
  Tremor                      +(P3)                                                                                              +(P30, 35, 38, 41, 45)                                                +(P19, 22, 24)                     +(P14, 17)   −        −                                                +(P13)                                             +(P49)
  UL predominant              −                                                                                                  −                                                                     −                                  −            −        −                                                +(P13)                                             −
  Scoliosis                   +(P1, 2, 4)                                                                                        +(P29,31, 35, 37, 39, 41, 42, 43, 45)                                 +(P25)                             +(P15)       −        −                                                +(P12[a](#brb3451-note-0004){ref-type="fn"})       −
  Hand deformities            +(P1, 10)                                                                                          +(P40)                                                                −                                  −            −        −                                                −                                                  −
  Skeletal deformities        −                                                                                                  Hip dysplasia bilat. (P33, 42, 45)                                    −                                  −            −        Ulnar deviation of hands, hyper−kyphosis (P47)   −                                                  −
  Deafness                    −                                                                                                  +(P35)                                                                −                                  −            −        −                                                −                                                  −
  Cognitive impairment        +(P1, 7)                                                                                           +(P30)                                                                −                                  −            −        −                                                +(P13)                                             −
  Bulbar                      −                                                                                                  Dysphagia (P35)                                                       −                                  −            −        −                                                −                                                  −
  Fasciculations              +(P10)                                                                                             −                                                                     +(P19)                             −            −        −                                                −                                                  −
  Facial weakness             −                                                                                                  +(P28, 30, 32, 45)                                                    +(P18)                             −            −        −                                                −                                                  −
  Pain                        +(P1, 7)                                                                                           +(P31, 34, 35, 36, 39, 40, 41, 45)                                    +(P22)                             +(P14, 15)   −        −                                                +(P12[a](#brb3451-note-0004){ref-type="fn"}, 13)   +(P48)
  Paresthesia                 +(P1, 5, 6, 7)                                                                                     +(P27, 32, 35, 38, 40, 41)                                            +(P19, 26)                         +(P14, 17)   +(P46)   −                                                +(P12[a](#brb3451-note-0004){ref-type="fn"}, 13)   +(P48)
  Early onset                 +(P1)                                                                                              −                                                                     −                                  −            −        −                                                −                                                  −
  Eye involvement             Pupillary (P2, 4, 5)                                                                               −                                                                     −                                  −            −        −                                                −                                                  −
  CTS                         +(P4, 7)                                                                                           \+ (P40, 45)                                                          +(P24)                             −            −        −                                                +(P13)                                             −
  Respiratory insufficiency   Restrictive +(P10)                                                                                 +(P30), elevated diaphragm (P37)                                      −                                  −            −        −                                                −                                                  −
  Autonomous                  Bladder urgency (P1), postural hypotension (P7), urinary incon‐tinence (P7), hyperhidrosis (P11)   Incontinence (P36), hyperhidrosis (P38), postural hypotension (P34)   Slowed emptying of stomach (P20)   −            −        −                                                Postural hypoten‐sion (P13)                        Bladder urgency (P49)
  Brain MRI                   Vascular leucencepha‐lopathia and plump lateral ventricles (P6, MRI at age 65y)                    −                                                                     −                                  −            −        −                                                −                                                  −
  Hypertrophic nerve roots    +(P2, 4, 6)                                                                                        −                                                                     −                                  −            −        −                                                −                                                  −
  RLS                         +(P1)                                                                                              +(P40, 45)                                                            +(P24, 26)                         +(P17)       −        −                                                +(P12[a](#brb3451-note-0004){ref-type="fn"}, 13)   +(P48)
  Cold‐induced hand cramps    +(P7)                                                                                              +(P39, 40)                                                            +(P24)                             −            −        −                                                −                                                  +(P48)
  ESRD, proteinuria, GS       −                                                                                                  −                                                                     −                                  −            −        +(P47)                                           −                                                  −

CMT1A, Charcot--Marie--Tooth neuropathy type 1A; HNPP, hereditary neuropathy with liability to pressure palsies; P, patient; UL, upper limb; bilat., bilateral; CTS, carpal tunnel syndrome; MRI, magnetic resonance imaging; RLS, restless legs syndrome; ESRD, end‐stage renal disease; GS, glomerular sclerosis.

Multiple sclerosis as additional disease in this patient. For abbreviations of genes, see text and Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}.
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Molecular genetic analyses {#brb3451-sec-0009}
--------------------------

The molecular genetic tests were performed using genomic DNA from total peripheral blood samples following standard procedures, after obtaining patients\' written informed consent. Sanger sequencing or multiplex ligation‐dependent probe amplification (MLPA) combined with microsatellite marker method was performed in 46 CMT patients. A molecular genetic analysis of *INF2* was conducted in two patients with a polyneuropathy and histologically proven FSGS (from the initial cohort of 20 patients with FSGS, see above). NGS‐based panel diagnostics for mutations in 71 CMT‐causing genes was done in three patients (patients 6, 10, and 46; Tables [1](#brb3451-tbl-0001){ref-type="table-wrap"} and [2](#brb3451-tbl-0002){ref-type="table-wrap"}), in whom previous single‐gene analyses had not revealed a causative mutation. In addition, a segregation analysis was performed in two families (patient 1 with healthy mother and healthy sister; patients 7, 8, 9 with healthy mother and affected father -- family 2; Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). We used the prediction programs SIFT (sorting intolerant from tolerant algorithm), PolyPhen2 (polymorphism phenotyping version 2), and Provean Sift (protein variation effect analyzer) to verify pathogenicity of the identified variants (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}).

Literature search and meta‐analysis {#brb3451-sec-0010}
-----------------------------------

In order to study the additional features reported in CMT patients so far, we conducted a systematic review in PubMed from 1985 to 2014. We included published CMT patients in whom a genetic defect was identified, and excluded patients with other hereditary neuropathies, such as hereditary motor neuropathies (HMN) or hereditary sensory (and autonomic) neuropathies (HSN, HSAN). CMT patients with compound heterozygous mutations in two different genes were also excluded, since no unequivocal genotype--phenotype correlation could be made. These criteria led to 280 publications that have been included in this study (Appendix S1).

Results {#brb3451-sec-0011}
=======

Patient cohort {#brb3451-sec-0012}
--------------

Our study cohort included 49 patients with a genetically confirmed diagnosis of CMT or HNPP (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). Nineteen patients belonged to eight different families and 30 patients were isolated cases. Six distinct mutations have been identified in the *MPZ* gene, of which three were novel (patients 1, 5; and patients 7, 8, 9 belonging to family 2) and predicted to be pathogenic by the three prediction programs applied (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). Furthermore, the variants co‐segregated with the disease status in the healthy mother and sister of patient 1, as well as in the healthy mother, affected father (patient 8) and brother (patient 9) of index patient 7. The two patients carrying the same c.293G\>A, p.R98H mutation in *MPZ* (patients 6 and 10) were not related. Eighteen patients carried a *PMP22* duplication, nine had a *PMP22* deletion, and one harbored a point mutation in the *PMP22* gene. In four patients, a pathogenic variant in the *GJB1* gene was identified, of which the c.303dup, p.E102Rfs\*8 mutation in *GJB1* in the related patients 16 and 17 was novel (brother and sister, family 4, Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). Two patients belonging to the same family (mother and son) carried a mutation in the lipopolysaccharide‐induced tumor necrosis factor‐*α* factor (*LITAF*) gene, one in the neurofilament protein light polypeptide (*NEFL*) gene, one in *INF2*, and two in the mitofusin 2 (*MFN2*) gene. The patient with *INF2* mutation has been described previously (Roos et al. [2015](#brb3451-bib-0029){ref-type="ref"}). Neuropathy severity, measured using the CMTNS2 score, was mild in seven patients (range 0--10), moderate in 13 (range 11--20), and severe in 17 cases (\>20). Genetic data, CMTNS2 scores, and CMT subtype of the patients are summarized in Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}.

Associated symptoms and signs {#brb3451-sec-0013}
-----------------------------

The additional features that were ascertained in our CMT patient cohort are listed in Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}. A total of 65% (32/49) of the patients presented two or more additional symptoms, 23% (11/49) had one, and 12% (6/49) expressed no additional features (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}).

### Hypertrophic cauda equina or nerve roots {#brb3451-sec-0014}

MRI of the spine revealed a hypertrophic cauda equina in three patients with a mutation in *MPZ* (CMT1B): in a brother and sister (patients 2 and 4) belonging to family 1 and in a third unrelated patient with a distinct *MPZ* mutation (patient 6) (Tables [1](#brb3451-tbl-0001){ref-type="table-wrap"} and [2](#brb3451-tbl-0002){ref-type="table-wrap"}; Fig. [1](#brb3451-fig-0001){ref-type="fig"}). The affected father of patients 2 and 4 (patient 3) was not available for MRI examination and patient 10, who harbored the same *MPZ* mutation as patient 6, could not undergo the examination due to marked respiratory insufficiency. We did not find hypertrophic nerve roots or cauda fascicles in the two patients with a mutation in *LITAF* (CMT1C), who underwent a cervical (patient 12) or lumbar MRI (patient 13). In the other study patients, a spinal MRI was not performed. Hypertrophy of cranial nerves was not additionally revealed on brain MRI in patients 2 and 6, neither in the other patients (patients 1, 5 12, 22) in whom a brain MRI was available (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}).

![Thoraco‐lumbo‐sacral MRI and sural nerve biopsies in three CMT1B patients with *MPZ*‐mutation and hypertrophic cauda equina/nerve roots. (A--C) T2‐weighted sagittal sections of the thoracal, lumbar, and sacral spinal column in patients 6 (A), 4 (B), and 2 (C), indicating the thickened nerve roots of the cauda equina (arrows). This is also shown for patient 2 at a T1‐weighted sagittal section (D) and a T1‐weighted coronal section (E). Arrow heads show congested intraspinal vessels. (F--H) T2‐weighted axial sections at the level of the fourth lumbar vertebral body (L4) of patients 6 (F), 4 (G) and 2 (H), showing extensive hypertrophic nerve roots of the cauda equina inside the spinal column. (I--K) Nerve Biopsy pictures of patients 6 (I, J) and 2 (K) with (J) being a magnification of (I). Arrow heads show onion bulb formations, the arrow points toward a remaining hypomyelinated nerve fiber. Notice the extensive loss of the large myelinated fibers.](BRB3-6-e00451-g001){#brb3451-fig-0001}

#### Clinical presentation of the three patients with MPZ mutation and hypertrophic nerve roots {#brb3451-sec-0015}

Patients 2 and 4 (brother and sister) had disease onset in childhood (patient 2) and at 38 years of age (patient 4) and patient 6 at 62 years (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). They presented typical symptoms and signs of CMT. Additional symptoms were scoliosis, anisocoric, and tonic pupils in patient 2, bilateral carpal tunnel syndrome (CTS), tonic pupils, and scoliosis in patient 4, and a sleep apnea syndrome in patient 6. Pupils could not be evaluated in patient 6 due to previous bilateral cataract surgery. Patient 4 complained of lower back pains and patient 6 of occasional lumbar pain radiating in the legs, which can be explained by the hypertrophic lumbar nerve roots.

NCVs were within the range of demyelinating CMT with motor NCV in the upper limbs of 19 m/sec (patient 2), 26 m/sec (patient 4), and 18 m/sec (patient 6). Liquor analysis in patients 2 and 6 revealed elevated protein levels (1.45 g/L and 0.46 g/L, respectively, normal value 0.15--0.45 g/L), and was not performed in patient 4. Spinal MRI in the three patients demonstrated bilaterally multiple enlarged nerve roots within the spinal column at the lumbar and sacral level (Fig. [1](#brb3451-fig-0001){ref-type="fig"}A--H), leading to congested intraspinal vessels (Fig. [1](#brb3451-fig-0001){ref-type="fig"}A--C and E). Sural nerve biopsies showed a prominent loss of large myelinated fibers (Fig. [1](#brb3451-fig-0001){ref-type="fig"}I--K), as well as Schwann cells forming multiple layers of myelin sheaths around lost fibers leading to onion bulb formations (Fig. [1](#brb3451-fig-0001){ref-type="fig"}J and K).

Our revision of the literature revealed the occurrence of hypertrophic nerve roots at the cervical and/or lumbar spine in association with *MPZ* mutations: c.306delA in two patients and c.167G\>A in another two cases, as well as *PMP22* gene alterations in five cases, of which three patients with *PMP22* duplication, one with a homozygous *PMP22* duplication, and one carrying a *PMP22* point mutation (Appendix S1). In our study, we added two distinct *MPZ* mutations associated with this feature (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). Furthermore, hypertrophy of the cranial nerves has also been described in two patients with a *MPZ* mutation and in another two with a *PMP22* gene deletion (Appendix S1).

### Restless legs syndrome {#brb3451-sec-0016}

Restless legs syndrome (RLS) was present in nine patients of our cohort (18%), five females and four males, aged 27, 32, 33, 39, 51, 54, 56, 63, and 65 years. They carried a mutation in the *MPZ*,*GJB1*, or *MFN2* gene (one patient each), in *LITAF* (two patients), or a *PMP22* duplication (two patients) or deletion (two patients). CMT patients with RLS had CMTNS2 scores ranging from mainly severe (patient 1, 40, 45, 13), to moderate (patient 17) or mild neuropathy (patient 12) (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}).

In the literature, RLS has been associated with three different CMT genes (Appendix S1), among them also the genes that we have identified in our patient group, except for the *LITAF* and *MFN2* genes that were novel findings in our study.

### Respiratory insufficiency and scoliosis {#brb3451-sec-0017}

In patient 10 with CMT2‐I/J caused by a *MPZ* mutation, a severe restrictive respiratory insufficiency with vital capacity of 1.2 L (36.8% of the theoretical value) leading to severe dyspnea and orthopnea was diagnosed at the age of 48 years. Respiratory symptoms started at least 6 years before. Neurological examination at 48 years revealed distally pronounced weakness and sensory loss, pes cavus, clawed hands, and fasciculations at the extremities. She reported onset of CMT symptoms between 20 and 25 years of age. Due to pronounced orthopnea, the patient was not able to lie down, slept in sitting position, and needed a CPAP mask for sufficient oxygenation. Interestingly, patient 6 with the same R98H mutation in MPZ showed no signs of respiratory compromise (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}). Furthermore, we diagnosed respiratory insufficiency with a vital capacity of 1.91 L (54% of the theoretical value) at 25 years of age in patient 30 harboring a *PMP22* duplication. CMTNS2 scores were severe in both patients (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). They did not have a scoliosis as a possible cause of respiratory problems.

Mild scoliosis was noted in 14 patients and in one patient (patient 41, CMT1A), scoliosis was severe, necessitating a surgical correction. Three had a mutation in *MPZ* (CMT1B), eight had a *PMP22* duplication, one a *PMP22* point mutation, one a *PMP22* deletion, one carried a *GJB1* mutation, and one patient had a mutation in *LITAF* (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}).

Literature findings revealed that respiratory insufficiency and scoliosis are frequent additional features in many different CMT subtypes including those that we have detected (Appendix S1).

### Pupillary abnormalities {#brb3451-sec-0018}

Pupillary abnormalities were noticed in three of our patients with a *MPZ* mutation. Two of them had the CMT1B phenotype (patients 2 and 4) and showed tonic pupils and/or anisocoria. The third patient, with CMT2 I/J (patient 5), presented tonic pupils, anisocoria, and mydriasis (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}). In patients 3 and 6, reactions to light were not measurable because of a previous bilateral cataract surgery. CMTNS2 scores in our patients with pupillary abnormalities were in the range of mild (patients 4 and 5) or moderate (patient 2) neuropathy severity (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}).

Our literature review revealed that pupillary abnormalities have been reported with mutations in 10 different CMT‐causing genes (Appendix S1). Most frequently occurring abnormalities are tonic pupils \[*PMP22, MPZ, GJB1,* SH3 domain, and tetratricopeptide repeat domain 2 (*SH3TC2*) gene*,* set‐binding factor 1 (*SBF1*) gene\], or an impaired pupillary reaction \[transient receptor potential cation channel subfamily V, member 4 (*TRPV4*) gene, NMYC downstream‐regulated gene 1 (*NDRG1*) gene\]. Furthermore, anisocoria \[*PMP22, MPZ, MFN2, SH3TC2*; FYVE, RhoGEF, and PH domain‐containing protein 4 (*FGD4*) gene\], miosis (*PMP22, MPZ*) and mydriasis (*MPZ*) have been described previously.

### Cold‐induced hand cramps {#brb3451-sec-0019}

In our cohort, cold‐induced hand cramps were indicated during history taking by one patient with *MPZ* mutation (CMT1B, patient 7), two cases with *PMP22* duplication (patients 39, 40), one patient with *PMP22* deletion (patient 24), and one with a mutation in *MFN2* (patient 48) (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}).

In contrast to our findings, literature data revealed this symptom only in association with a mutation in the glycyl‐tRNA synthetase (*GARS*) gene (Appendix S1).

### Focal segmental glomerular sclerosis {#brb3451-sec-0020}

In one of the two patients with histologically proven FSGS and a polyneuropathy, we identified a pathogenic mutation in the *INF2* gene (patient 47). Literature findings confirmed that renal problems and FSGS in particular in CMT patients occur so far exclusively in association with mutations in *INF2*. In addition, deafness, cerebral white matter hyperintensities, and enlarged ventricles have been described in association with *INF2* mutations (Appendix S1). These features were, however, not present in our patient.

Summary of associated features in CMT {#brb3451-sec-0021}
-------------------------------------

Considering our study cohort and literature data, we detected more than 80 different additional symptoms or signs associated with CMT (Appendix S1, Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}). Table [3](#brb3451-tbl-0003){ref-type="table-wrap"} summarizes the new findings in our cohort compared to the literature (Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}).

###### 

Additional symptoms identified in our CMT cohort and occurrence in the literature

  ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Autonomous: U urgency/incontinence                                  [*PMP22*]{.ul},[*MPZ*]{.ul},**MFN2**,LRSAM1,TRPV4,SBF1

  Autonomous: Postural hypotension                                    **PMP22**,[*MPZ*]{.ul},**LITAF**

  Autonomous: Hyperhidrosis                                           **PMP22**,**MPZ,**MFN2,GDAP1

  Bulbar (dysphagia, dysarthria, cranial nerve involvement of IX/X)   [*PMP22*]{.ul},MPZ,GJB1,EGR2,MFN2,GDAP1,NEFL,SH3TC2,MTMR2,TFG,NDRG1,IFRD1,TRPV4,SBF1

  Cognitive impairment                                                [*PMP22*]{.ul},**MPZ**,GJB1,MFN2,INF2,DYNC1H1,NEFL,DNM2,**LITAF**,SLC12A6,HK1,AIFM1,SBF1

  Cold‐induced hand cramps                                            **PMP22**,**MPZ**,**MFN2**,GARS

  Carpal tunnel syndrome                                              **PMP22**,**MPZ**,PRX,**LITAF**,FIG 4,TRPV4,FBLN5

  Deafness                                                            [*PMP22*]{.ul},MPZ,GJB1,PRX,EGR2,MFN2,PDK3,SURF1,INF2,NEFL,AARS,LRSAM1,SH3TC2,TFG,LITAF,SBF2,NDRG1,IFRD1\
                                                                      TRPV4,AIFM1,PRPS1

  Early onset:                                                        PMP22,[*MPZ*]{.ul},GJB1,PRX,EGR2,MFN2,PDK3,GDAP1,INF2,DYNC1H1,NEFL,TRIM2,KARS,SH3TC2,FIG 4,DNM2,MTMR2\
                                                                      FGD4,NDRG1,TRPV4,SCL12A6,AIFM1

  Eye: Pupillary                                                      PMP22,[*MPZ*]{.ul},GJB1,EGR2,MFN2,SH3TC2,FGD4,NDRG1,TRPV4,SBF1

  Facial weakness                                                     [*PMP22*]{.ul},MPZ,EGR2,MFN2,GDAP1,NEFL,SH3TC2,FIG 4,DNM2,MTMR2,NDRG1,TRPV4,TRG,SLC12A6,HK1,SBF1

  Fasciculations                                                      PMP22,**MPZ**,PRX,EGR2,NEFL,HINT1,LRSAM1,SH3TC2,RAB7,TFG,HSPB1,AIFM1

  Hand deformities                                                    [*PMP22*]{.ul},[*MPZ*]{.ul},PRX,EGR2,GDAP1,INF2,LMNA,NEFL,SH3TC2,FIG 4,MTMR2,SBF2,NDRG1,HSPB1,HK1,FBLN5

  MRI, brain: White matter involvement                                PMP22,[*MPZ*]{.ul},GJB1,MFN2,INF2,SH3TC2,NDRG1,SLC12A6,AIFM1

  MRI, spinal: Hypertrophic nerve roots                               PMP22,[*MPZ*]{.ul}

  Pain                                                                [*PMP22*]{.ul},[*MPZ*]{.ul},**GJB1**,[*MFN2*]{.ul},GDAP1,INF2,DYNC1H1,MARS,HARS,SH3TC2,RAB7,FIG 4,TFG,[*LITAF*]{.ul},SBF2,HSPB1

  Paresthesia                                                         [*PMP22*]{.ul},[*MPZ*]{.ul},[*GJB1*]{.ul},PRX,**MFN2**,**NEFL**,FIG 4,DNM2,TFG,[*LITAF*]{.ul},HSJ1,MED25,FBLN5

  Renal problems                                                      [*INF2*]{.ul}

  Respiratory insufficiency                                           **PMP22**,[*MPZ*]{.ul},PRX,EGR2,MFN2,GDAP1,SH3TC2,FIG 4,MTMR2,TFG,TRPV4,FBLN5

  Restless legs syndrome                                              [*PMP22*]{.ul},[*MPZ*]{.ul},[*GJB1*]{.ul},**MFN2**,**LITAF**

  Skeletal: Congenital hip dysplasia                                  [*PMP22*]{.ul},EGR2

  Skeletal: Hyperkyphosis                                             **INF2**,PRX,MFN2,GDAP1,SLC12A6

  Skeletal: Scoliosis                                                 [*PMP22*]{.ul},[*MPZ*]{.ul},[*GJB1*]{.ul},PRX,EGR2,MFN2,GDAP1,SURF1,INF2,LMNA,NEFL,GARS,SH3TC2,RAB7,FIG 4,MTMR2,[*LITAF*]{.ul},FGD4\
                                                                      SBF2,NDRG1,HSPB8,TRPV4,HK1,FBLN5,SBF1

  Skeletal: Ulnar deviation of hands                                  PMP22,**INF2**

  Tremor                                                              [*PMP22*]{.ul},[*MPZ*]{.ul},[*GJB1*]{.ul},PRX,EGR2,[*MFN2*]{.ul},PDK3,INF2,DYNC1H1,NEFL,SH3TC2,FIG 4,TFG,[*LITAF*]{.ul},FGD4,NDRG1,IFRD1,TRPV4\
                                                                      SCL12A6,HK1

  Upper limb predominant                                              **LITAF**,GARS
  ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------

Bold: new findings in current patient cohort; italics and underlined: findings in current study that have been reported previously; not underlined, not italics and not bold: literature findings. CMT, Charcot--Marie--Tooth neuropathy; U, urinary. Additional features are listed in alphabetical order.

John Wiley & Sons, Ltd

Regarding the additional features of all CMT‐causing genes described in the literature, many additional features were reported in association with many distinct CMT‐causing genes, for example, vocal cord involvement, tremor, scoliosis, hand deformities (claw hands and/or finger contractures), deafness, cognitive impairment, bulbar symptoms, fasciculations, facial weakness, early proximal weakness, pain, paresthesias, early onset CMT, pupillary abnormality, ophthalmoparesis, respiratory failure/distress, SAS, dysmorphic features, central nervous system/cranial nerve involvement, brain imaging abnormality, white matter involvement, severe slow NCV, and kyphosis/lordosis (Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}, Appendix S1).

On the contrary, other additional symptoms were described in a single patient or family only and in association with only one gene, such as optic neuritis, chronic vomiting, bowel dysfunction, mutilating arthropathy, nocturnal vomiting, hyperkeratosis, myokymia, cardiac insufficiency and cardiomyopathy, involuntary movements, edema, self‐abusive behavior, acrocyanosis, lactic acidosis under fasting conditions, and slowed emptying of stomach (Appendix S1).

Link between additional features and gene function? {#brb3451-sec-0022}
---------------------------------------------------

We studied whether the occurrence of certain additional symptoms might be related to mutations in genes that express a similar function. We considered as distinct functional groups (Azzedine et al. [2012](#brb3451-bib-0002){ref-type="ref"}; Timmerman et al. [2013](#brb3451-bib-0039){ref-type="ref"}): genes expressing a role in myelination, mitochondrial functioning, cytoskeletal stability and motor proteins, RNA and protein metabolism, protein folding, membrane traffic, transcription regulation, channel or transporter and other/unknown (Appendix S1). However, we did not find a correlation between the additional features and the function of the causative genes.

Mutations identified in our cohort compared with the same mutations reported in the literature {#brb3451-sec-0023}
----------------------------------------------------------------------------------------------

We compared the clinical phenotype and in particular the associated features related to the mutations identified in our cohort with literature findings on the same mutations (Appendix S2). If clinical data were not available in addition to the mutation in the literature, the respective publication was not included in the Appendix S2.

Discussion {#brb3451-sec-0024}
==========

We showed that the majority of CMT patients presented one or more feature in addition to the classical CMT phenotype. Several additional features revealed by our study, such as hypertrophic nerve roots and RLS, seem to be underestimated. Their occurrence broaden the clinical spectrum and genotype--phenotype associations in CMT.

Methodological issues of our study and future perspectives {#brb3451-sec-0025}
----------------------------------------------------------

Due to the partly retrospective nature of our study, some data such as MRI images or nerve biopsies were lacking in some patients. Furthermore, although our overall patient cohort was large considering the rarity of the disease, some of the subgroups, such as CMT1F and CMT2A2, were small. However, we additionally included in our study all data of the currently available literature (in total 280 papers, Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}, Appendices S1 and S2), in order to obtain more data and larger subgroups. Our results are very interesting, but prospective larger multicenter studies will be necessary in the future to confirm our findings.

Hypertrophic nerve roots as additional finding in patients with CMT {#brb3451-sec-0026}
-------------------------------------------------------------------

Hypertrophic nerve roots can occur in hereditary disorders (e.g., CMT1, CMT3, neurofibromatosis), infectious or inflammatory neuropathies, neoplastic nerve disorders, and diverse acquired diseases such as amyloidosis (Ginsberg et al. [1995](#brb3451-bib-0016){ref-type="ref"}). Hypertrophied nerve roots in CMT have been reported previously by using pathological, ultrasonographic, and MRI examinations (Andermann et al. [1962](#brb3451-bib-0001){ref-type="ref"}; Symonds and Blackwood [1962](#brb3451-bib-0038){ref-type="ref"}; Marchini et al. [2009](#brb3451-bib-0024){ref-type="ref"}; Sugimoto et al. [2013](#brb3451-bib-0037){ref-type="ref"}). Thus, the presence of hypertrophic nerve roots in CMT is not new, and is probably often not reported since there is rarely a compelling reason to perform MRI in patients with CMT. So far, two CMT‐causing genes, *PMP22* and *MPZ,* have been related to this feature (Butefisch et al. [1999](#brb3451-bib-0007){ref-type="ref"}; Kleopa et al. [2002](#brb3451-bib-0022){ref-type="ref"}; Simonati et al. [2002](#brb3451-bib-0033){ref-type="ref"}; Marchini et al. [2009](#brb3451-bib-0024){ref-type="ref"}) (Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}, Appendix S1). Also in our cohort, three CMT1B patients with a *MPZ* mutation presented a hypertrophic cauda equina. In contrast to another case in which the hypertrophic nerve roots and cauda resulted in a compression with severe symptoms and improvement by surgery (Kleopa et al. [2002](#brb3451-bib-0022){ref-type="ref"}), our patients did not show signs of medullar compression. Interestingly, we observed hypertrophic nerve roots in two relatives with CMT1B (brother and sister, family 1) as well as in a third unrelated individual. The two mutations in the *MPZ* gene that were associated with this feature in our study (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}), have been described in the literature before; however, in those cases, hypertrophic nerve roots were not reported (Appendix S2). Hypertrophic nerve roots in CMT1B‐patients were mainly described in isolated cases (Kleopa et al. [2002](#brb3451-bib-0022){ref-type="ref"}; Simonati et al. [2002](#brb3451-bib-0033){ref-type="ref"}) and in only one family comprising a father and his two affected daughters carrying the Val102 fs mutation in *MPZ* (Marchini et al. [2009](#brb3451-bib-0024){ref-type="ref"}). Hypertrophic nerve roots caused by mutations in *MPZ* were not only found in association with the CMT1B phenotype, but also with congenital hypomyelinating neuropathy (CHN) (Simonati et al. [2002](#brb3451-bib-0033){ref-type="ref"}) and Dejerine--Sottas neuropathy (DSS) (Kleopa et al. [2002](#brb3451-bib-0022){ref-type="ref"}). Most authors presume that the thickening of nerve roots is due to a Schwann cell proliferation in the context of consistent de‐ and remyelination over the years (Kleopa et al. [2002](#brb3451-bib-0022){ref-type="ref"}; Simonati et al. [2002](#brb3451-bib-0033){ref-type="ref"}). This explanation is further strengthened by the finding that the number of onion bulb formations in sural nerve biopsies, indicating active de‐ and remyelination, correlated with the occurrence of spinal nerve root enhancement and thickening on lumbosacral MRI in CMT patients (Cellerini et al. [2000](#brb3451-bib-0008){ref-type="ref"}).

RLS as additional symptom in CMT {#brb3451-sec-0027}
--------------------------------

RLS was present in 18% of our cohort, which was higher compared to the prevalence of 9.8% in the general population above 65 years of age (Rothdach et al. [2000](#brb3451-bib-0031){ref-type="ref"}). In our cohort, five females (19% of all females, aged 32, 51, 54, 56, and 65 years) and four males (18% of all males, aged 27, 33, 39, and 63 years) were affected. In contrast to these quite similar numbers, women in the general population were found to be affected twice as often as men (13.9% vs. 6.1%) (Rothdach et al. [2000](#brb3451-bib-0031){ref-type="ref"}) and also female CMT patients showed RLS more frequently than male CMT patients in previous studies (Boentert et al. [2010](#brb3451-bib-0003){ref-type="ref"}, [2014](#brb3451-bib-0004){ref-type="ref"}). The prevalence of RLS has previously been shown to be significantly increased in hereditary neuropathies, including CMT1, CMT2, CMTX, and HNPP (Hattan et al. [2009](#brb3451-bib-0018){ref-type="ref"}). Since RLS is frequently associated with peripheral neuropathy in general, our findings were, however, to be expected (Hattan et al. [2009](#brb3451-bib-0018){ref-type="ref"}). In our cohort, eight out of nine patients with RLS harbored demyelinating subtypes with mutations in the *MPZ* (*n* = 1), *GJB1* (*n* = 1), or *LITAF* gene (*n* = 2) or a *PMP22* duplication (*n* = 2) or deletion (*n* = 2) and one patient with RLS displayed an axonal neuropathy with *MFN2* gene mutation (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}). In the literature, RLS was described in cohorts consisting of CMT patients with *PMP22* duplication and *MPZ* or *GJB1* gene mutation (Appendix S1). Female CMT patients were also found to be more severely affected by RLS than men (Boentert et al. [2010](#brb3451-bib-0003){ref-type="ref"}, [2014](#brb3451-bib-0004){ref-type="ref"}). In our cohort, four patients suffering from RLS had severe (two male and two female, patient 1, 40, 45, 13), one moderate (male, patient 17), and one mild neuropathy (male, patient 12) (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). One hypothesis is that axonal atrophy increases axonal excitability in primary sensory units of leg muscles which results in creeping sensations (Iannaccone et al. [1995](#brb3451-bib-0021){ref-type="ref"}). As a consequence, this sensory input in the central nervous system may lead to the oscillatory leg movements typical for RLS (Iannaccone et al. [1995](#brb3451-bib-0021){ref-type="ref"}). This hypothesis links axonal atrophy with RLS. In CMT patients, axonal damage may occur in axonal subtypes as well as in demyelinating subtypes, where it develops consequently to the loss of myelin (Boentert et al. [2010](#brb3451-bib-0003){ref-type="ref"}). This might explain how CMT may predispose to RLS.

Pupillary abnormalities as additional feature in CMT patients {#brb3451-sec-0028}
-------------------------------------------------------------

In our cohort, pupillary abnormalities were seen in three out of 11 patients with a *MPZ* gene mutation (27%): two CMT1B patients belonging to one family (patients 2 and 4) and one isolated CMT2‐I/J patient (patient 5) (Tables [1](#brb3451-tbl-0001){ref-type="table-wrap"} and [2](#brb3451-tbl-0002){ref-type="table-wrap"}). Their pupil changes became apparent at 51, 41, and 23 years of age, respectively. In another eight patients with *MPZ* gene mutation, one CMT2 and seven CMT1, we did not detect pupil changes (Tables [1](#brb3451-tbl-0001){ref-type="table-wrap"} and [2](#brb3451-tbl-0002){ref-type="table-wrap"}). Families and isolated CMT patients have been described with pupillary abnormalities harboring mutations in 10 different CMT‐causing genes, including the *MPZ* gene (Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}, Appendix S1). Certain *MPZ* mutations were found to be particularly associated with pupil abnormalities, such as the Thr124Met mutation leading to CMT2‐I/J in most patients. This mutation is associated with a distinct clinical phenotype including late onset in the fourth or fifth decade, pupillary abnormalities, shooting pains, deafness, explicit sensory disturbances, rapid progression, various autonomic system involvement, and respiratory insufficiency (De Jonghe et al. [1999](#brb3451-bib-0011){ref-type="ref"}; Stojkovic et al. [2003](#brb3451-bib-0035){ref-type="ref"}). Patient 5 of our cohort also showed the CMT2‐I/J phenotype with pupillary abnormalities associated with the novel *MPZ* mutation Gly123Ala (Table [1](#brb3451-tbl-0001){ref-type="table-wrap"}). She complained of painful paresthesia in the lower limbs, hands, and face, compatible with the lancinating pains described in patients with the Thr124Met mutation. In contrast, her disease symptoms already began in the third decade, disease progression was rather slow, and no further associated features such as deafness or autonomic system involvement were present (Table [2](#brb3451-tbl-0002){ref-type="table-wrap"}).

Conclusions {#brb3451-sec-0029}
===========

We conclude that additional features are present in the majority of CMT patients. In case of rather specific features, occurring in association with only one (e.g., renal problems) or a few different CMT genes (e.g., hypertrophic nerve roots, Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}), they might be used to guide genetic diagnosis by performing one or only a few single‐gene analyses. However, many other additional symptoms, such as hearing impairment or cognitive involvement, can present in association with a large number of distinct genes (Table [3](#brb3451-tbl-0003){ref-type="table-wrap"}, Appendix S1), which hampers a gene search based on the additional features. Therefore, in these cases, it might diagnostically be more efficient to directly perform novel genetic techniques (WES), in which a large number of genes can be tested at the same time. However, aside from additional clinical features, the mode of inheritance, NCVs, and pathological examination of nerve biopsies also remain important clues to molecular diagnosis in CMT.

Conflict of Interest {#brb3451-sec-0031}
====================

The authors declare that they have no conflicts of interest.

Supporting information
======================

###### 

**Appendix S1.** Additional symptoms and features in patients with CMT reported in the literature.
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**Appendix S2.** Phenotypic comparison of mutations found in our cohort with the literature.
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Click here for additional data file.

We thank the patients and their families for participating in our study. We are grateful to the technical and administrative personnel of the Department of Neurology, the Institute of Neuropathology and the Department of Neuroradiology of the University Hospital Aachen for their support. The study was funded by a research grant to K. G. Claeys provided by the Deutsche Gesellschaft für Muskelkranke e.V. (DGM).
